Literature DB >> 17334648

Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.

Yan Sun1, Zhi Li, Lijun Li, Jing Li, Xiaobo Liu, Wenxin Li.   

Abstract

RNA interference (RNAi) mediated by double- stranded small interfering RNA (siRNA) is a novel mechanism of sequence-specific, post-transcriptional gene silencing. There has been much research into the use of RNAi for the treatment of human diseases. Many viruses, including hepatitis B virus (HBV), are susceptible to inhibition by this mechanism. However, for RNAi to be efficacious therapeutically, effective RNAi targeting sequences and a suitable delivery system are required. In this study, we employed a polymerase chain reaction (PCR)-based siRNA expression strategy to rapidly screen for effective siRNA sequences. Two effective siRNAs sequences (designated as S2 and X1) which reduced the HBV RNA by >90% were identified. For delivering the siRNAs, they were cloned into a human foamy virus (HFV)-based vector to generate single siRNA expression vectors HFVU6-siS2, HFVU6-siX1 and a dual siRNA expression vector HFVU6-siSX. The results showed that these siRNA vectors effectively inhibited multiple HBV gene expression and viral DNA replication based on ELISA and quantitative PCR analysis. HFVU6-siSX which simultaneously expressed two siRNAs that targeted the S and X genes of HBV is the most potent inhibitor of HBV replication. In addition, the repression of HBV RNA and DNA was stable for up to 3 months post-transduction as determined by RT-PCR and Southern blotting. Collectively, the PCR-based siRNA expression strategy provides a rapid and easy approach for testing candidate anti-HBV siRNA sequences and for cloning selected siRNA expression cassettes into a vector. RNAi based on the HFV vector was able to achieve effective, long-term inhibition of HBV gene expression and viral DNA replication. The combination of the two techniques may provide a powerful tool in the treatment of viral infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334648

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

2.  SYBR Green I-based product-enhanced reverse transcriptase assay for quantification of retroviral PFV and detection of the divalent cation preference of PFV RT.

Authors:  Xiaofang Yi; Yan Sun; Qingmei Liu; Zhi Li; Wanhong Liu; Xiaohua He; Linjuan Zhang; Yuxin Wang
Journal:  Virol Sin       Date:  2014-10       Impact factor: 4.327

3.  Inhibition of HCV 5'-NTR and core expression by a small hairpin RNA delivered by a histone gene carrier, HPhA.

Authors:  Yanhua Ding; Hong Zhang; Yuxiang Li; Di Wu; Shumei He; Yang Wang; Yuanyuan Li; Feng Wang; Junqi Niu
Journal:  Int J Med Sci       Date:  2013-06-09       Impact factor: 3.738

4.  Effects of HBV Genetic Variability on RNAi Strategies.

Authors:  Nattanan Panjaworayan; Chris M Brown
Journal:  Hepat Res Treat       Date:  2011-07-02

Review 5.  RNAi for treating hepatitis B viral infection.

Authors:  Yong Chen; Guofeng Cheng; Ram I Mahato
Journal:  Pharm Res       Date:  2007-12-12       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.